Amendments in the Claims

Claims 1 to 4 have been cancelled.

5. (Currently amended) The method as claimed in claim 16 ~~1~~, wherein the transgenic cells are produced in the course of a gene therapy treatment.

6. (Previously amended) The method as claimed in claim 5, wherein the gene therapy treatment is employed for the treatment of all disorders in which a protein or peptide is not produced, is produced inadequately, or only produced defectively in the body of the mammal.

7. (Previously amended) The method as claimed in claim 5, wherein the gene therapy treatment is employed for the treatment of hereditary disorders such as cystic fibrosis, familial hypercholesterolemia, hemophilia, sickle cell anemia; of nerve and brain disorders such as Parkinson's, Alzheimer's or Kreuzfeld-Jakop syndrome; of rheumatic disorders, osteoarthritis, osteoporosis or arthrosis, of phenylketonuria; of metabolic disorders, such as diabetes; of inflammations; of carcinomatous disorders; of infectious disorders, for example AIDS or hepatitis or of hormone and growth disorders.

8. (Previously amended) The method as claimed in claim 5, wherein the gene therapy treatment is employed in order to generate a vaccine protection against disease pathogens such as viruses, bacteria, fungi, mono- and multicellular parasites and also against abnormal body cells such as tumor cells.

9. (Currently amended) The method as claimed in claim 16 ~~1~~, wherein the pharmaceutical is administered orally, intravenously, subcutaneously,

intraperitoneally, percutaneously, cutaneously, topically, by inhalation, intramuscularly, intrathecally, intraocularly, ocularly, buccally, nasally or rectally, preferably intravenously or orally.

10. (Previously amended) The method as claimed in claim 9, wherein the pharmaceutical is administered orally or intravenously.

11. (Currently amended) The method as claimed in claim 16 ~~1~~, wherein the mammal is man.

12. (Currently amended) The method as claimed in claim 16 ~~1~~, wherein the transgenic cells are transfected by means of a recombinant adenovirus vector.

13. (Previously presented) The method of claim 6, wherein the mammal is man.

14. (Previously presented) The method of claim 7, wherein the metabolic disorder is diabetes.

15. (Previously presented) The method of claim 7, wherein the infectious disorder is AIDS or hepatitis.

16. (Currently amended) A ~~In a~~ method for expressing a transgenic product in a mammal comprising introducing into a cell of said mammal a transgene capable of expressing said transgenic product and administering to said mammal an ~~immunosuppressant, the improvement comprising administering as the~~ immunosuppressant comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate in an amount such that the level of

said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 50% greater than the level of said product when said immunosuppressant is not administered, wherein said immunosuppressant is administered before, during, or after, or any combination thereof, administration of the transgenic product into the mammal.

17. (Previously presented) The method of Claim 16 wherein said immunosuppressant is administered in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 5 times greater than the level of said product when said immunosuppressant is not administered.

18. (Previously presented) The method of Claim 16 wherein said immunosuppressant is administered in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 10 times greater than the level of said product when said immunosuppressant is not administered.

19. (Withdrawn) A method for identifying a substance which has immunosuppressant properties and which remains capable, after its administration to a mammal has been discontinued, of suppressing the immune response of said mammal to a transgenic cell which is contained in the mammal and which expresses a transgenic product, said method comprising the step of comparing the level of said transgenic product produced by a transgenic cell contained in a first mammal which has been administered said substance with the level of said transgenic product produced by a transgenic cell contained in a second mammal which has not been administered said substance, said levels

being measured after the administration of said substance has been discontinued.

20. (Withdrawn) A method according to Claim 19 wherein the level of said transgenic product in said first and second mammals is measured 15 or more days after the administration of said substance has been discontinued.

21. (Withdrawn) A method according to Claim 19 wherein said transgenic cell is produced *in vivo* in said first and second mammals and the level of said transgenic product in said first and second mammals is monitored continuously from the time of the production of the transgenic cell.

22. (Withdrawn) A method according to Claim 19 wherein the level of said transgenic product in said first and second mammals is monitored continuously from the first day following the discontinuation of the administration of said substance.

23. (New) The method according to Claim 16 wherein said immunosuppressant is p15-deoxyspergualin.

24. (New) The method according to Claim 16 wherein said transgenic cells are produced *in vivo*.

25. (New) The method according to Claim 16 wherein said immunosuppressant is administered intravenously.

26. (New) A method for increasing the tolerance of a mammal to transgenic cells, wherein the transgenic cells are produced *in vivo* after the administration of a

vector including a transgene, by administering an immunosuppressant comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate to the mammal intravenously or intraperitoneally, before, during, or after, or any combination thereof, the administration of the vector, wherein a concomitant immunosuppressant therapy is discontinued.

27. (New) The method according to Claim 26 wherein said immunosuppressant is p15-deoxyspergualin.

28. (New) The method according to Claim 16 wherein said immunosuppressant is administered intravenously.

29. (New) A method for increasing the tolerance of a mammal to transgenic cells comprising introducing into a cell of said mammal a transgene capable of expressing said transgenic product and administering to said mammal an immunosuppressant comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 50% greater than the level of said product when said immunosuppressant is not administered, wherein said immunosuppressant is administered before, during, or after, or any combination thereof, administration of the transgenic cells.

30. (New) The method according to Claim 29 wherein said immunosuppressant is p15-deoxyspergualin.

31. (New) The method according to Claim 29 wherein said transgenic cells are

produced *in vivo*.

32. (New) The method according to Claim 29 wherein said immunosuppressant is administered intravenously.